8-(4-Methoxy-2-methylphenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino [1,2-a]quinoxaline | 444161-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 8-(4-Methoxy-2-methylphenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino [1,2-a]quinoxaline
• 英文别名: 8-(4-methoxy-2-methylphenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline
• CAS: 444161-32-4
• 化学式: C₁₉H₂₃N₃O
• 分子量: 309.411
• InChiKey: JCDTXSQPPHBCHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  36.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
  申请人：——

  公开号：US20020177596A1

  公开（公告）日：2002-11-28

  The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 4a , R 4b , R 5 , R 6 , R 7 , R 8 , R 9 , n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）和（I-a）表示的新化合物：1或其药学上可接受的盐，其中R1、R4a、R4b、R5、R6、R7、R8、R9、n和X在此处描述。本发明还涉及包含这些新化合物作为活性成分的药物配方，以及利用这些新化合物及其配方治疗某些疾病。本发明的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防包括肥胖、焦虑、抑郁、精神病、精神分裂症、睡眠和性功能障碍、偏头痛以及与头痛相关的其他情况、社交恐惧症和胃肠道疾病（如胃肠道运动功能障碍）等中枢神经系统疾病。
• FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：SHIRAI Junya

  公开号：US20120165312A1

  公开（公告）日：2012-06-28

  The present invention relates to a serotonin 5-HT 2C receptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HT 2C receptor activating action and the like.

  本发明涉及一种含有由以下式表示的化合物的血清素5-HT2C受体激动剂： 其中环A是一种5-或6-成员芳香杂环，可选地具有取代基，环B是一种7-至9-成员环，除了一个氧代基外还可选地具有取代基，其中m和n（m，n）的组合为（1，2），（2，1），（2，2），（3，1），（3，2）或（4，1），或其盐或前药，以及具有血清素5-HT2C受体激活作用的融合杂环化合物等。
• CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Matsumoto Takahiro

  公开号：US20100266504A1

  公开（公告）日：2010-10-21

  Provided are a condensed pyridine derivative having a serotonin 5-HT 2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT 2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT 2c receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种具有血清素5-HT2C受体激活作用的缩合吡啶衍生物，以及包含该缩合吡啶衍生物的预防或治疗下尿路症状、肥胖和/或器官脱垂等药物，以及增加膀胱内压力时增加泄漏点压力或预防或治疗压力性尿失禁的药物筛选方法，包含激活血清素5-HT2C受体的物质的预防或治疗膀胱脱垂或肠脱垂的药物，以及通过双侧切断动物的会阴神经和耻骨神经后增加膀胱内压力并测量尿道、直肠或阴道在此时观察到的闭合反应的膀胱脱垂或肠脱垂的治疗药物筛选方法。其中包含式的化合物的血清素5-HT2C受体激活剂：式中每个符号如规范中定义的那样，或其盐。
• PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1792629A1

  公开（公告）日：2007-06-06

  An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.

  一种预防或治疗压力性尿失禁的药物，其中含有一种能激活5-羟色胺5-HT2C受体的物质；一种预防或治疗压力性尿失禁的药物，其中含有一种能刺激雄激素结合位点的物质、以及一种筛选预防或治疗腹压性尿失禁药物的方法，其中包括电刺激动物的腹部肌肉或控制腹部肌肉的神经以增加腹压，并测量当时的漏点压力。
• Preventives/remedies for stress urinary incontinence and method of screening the same
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2248524A2

  公开（公告）日：2010-11-10

  APD-356 for use as an agent for the prophylaxis or treatment of stress urinary incontinence.

  APD-356 用于预防或治疗压力性尿失禁。